Kite Pharma
2225 Colorado Avenue
Santa Monica
California
90404
United States
Tel: 301-824-9999
Website: http://www.kitepharma.com/
Email: info@kitepharma.com
230 articles with Kite Pharma
-
This week has marked a number of stories over construction projects and real estate developers focused on the life sciences market. Here’s a look.
-
Arie Belldegrun, founder and former chair, president and chief executive officer of Kite Pharma, has teamed up with real estate developer Tishman Speyer to launch a biotech-focused real estate company, Breakthrough Properties.
-
Kite Announces Plans to Bolster Industry-Leading Cell Therapy Manufacturing Capabilities With New Viral Vector Facility
7/16/2019
Kite, a Gilead Company, announced plans for a new 67,000-square-foot facility in Oceanside, California, dedicated to the development and manufacturing of viral vectors, a critical starting material in the production of cell therapies.
-
At Kite, Shaw will focus on turning around the company's flagship CAR-T treatment Yescarta, as well as focus on the development of other cancer-targeting cell therapies.
-
At the American Society of Clinical Oncology meeting in Chicago, Kite presented updated safety data from the ZUMA-1 trial that introduced a regimen of steroids to CAR-T patients who show early signs of neurologic events reduces the safety concerns associated the CAR-T treatment.
-
Kite Announces End of Phase 1 ZUMA-3 Results for KTE-X19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
6/1/2019
Kite, a Gilead Company, announced results from the completed Phase 1 of the ZUMA-3 study evaluating KTE-X19, an investigational CD19 chimeric antigen receptor T cell therapy.
-
Biocartis and Kite Sign Agreement for Development of Assays supporting Kite’s Therapies
6/1/2019
Biocartis Group NV, an innovative molecular diagnostics company, announced that it has entered into a Master Development and Commercialization Agreement with Kite, a Gilead Company.
-
Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (Axicabtagene Ciloleucel) with Lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
5/31/2019
Kite, a Gilead Company, and Humanigen, Inc. (HGEN) announced today the formation of a clinical collaboration to conduct a Phase 1/2 study of lenzilumab, an investigational anti-GM-CSF monoclonal antibody, with Yescarta® in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
-
On Wednesday, Kite and Gilead announced the 20-acre facility in Fredericksburg that is expected to employ more than 400 people when it becomes operational.
-
While this type of personalized therapy is revolutionizing cancer treatment and healthcare, it has some formidable limitations.
-
Immuno-oncology has become a key lynchpin in the pipelines of many pharmaceutical companies. The global cancer immunotherapy market is expected to more than double over the next eight years to $126.9 billion by 2026.
-
A Look at a Few ASH Highlights: Gilead/Kite, Novartis, Celgene, Bluebird Bio, Seattle Genetics
12/3/2018
The American Society of Hematology Annual Meeting is always chock full of interesting research and development stories. Here’s a look at some of the highlights of the meeting so far, which is continuing today. -
The deal, which will last several years, has Tango performing target discovery and validation. Gilead will be able to option rights to up to five targets that come out of Tango’s work.
-
Allogene Therapeutics began trading on the Nasdaq Stock Exchange today under the ALLO ticker. The price was at the top of its range, $18 per share. The company plans to raise $288 million with the sale of about 16 million shares.
-
Merus Announces Formation of a Scientific Advisory Board
8/22/2018
Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced the formation of a Scientific Advisory Board (SAB), consisting of several world-renowned immuno-oncology and drug development professionals.
-
It’s not easy to predict trends in drugs, especially with breakthroughs in immunology and genetic engineering often causing dramatic changes in how biopharma companies approach new drugs.
-
Kite, a Gilead Company, And Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For The Treatment Of Cancer
2/22/2018
Kite to Receive Exclusive License to Leverage Sangamo's Gene Editing Technology in Allogeneic and Autologous Cell Therapy Programs in Oncology [22-February-2018] SANTA MONICA, Calif. and RICHMOND, Calif., Feb. 22, 2018 /PRNewswire/ -- Kite, a Gilead Company (Nasdaq: GILD) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced the companies have e
-
Gilead's $12B Bet Pays Off in Two Months After the FDA Approves Kite's Revolutionary CAR-T Therapy
10/19/2017
Maybe timing is everything. On Aug. 28, 2017, Gilead acquired Kite for about $11.9B. -
How Much Cash Kite Pharma's Execs Made From Its $12 Billion Gilead Deal
10/5/2017
-
Gilead Completes Tender Offer For All Outstanding Shares Of Kite Pharma
10/3/2017